(-)-CGP-12177 radioligand tritiated at the 5,7 position. CGP-12177 acts as an antagonist at the β1- and β2-adrenoceptors and a partial agonist at β3-adrenoceptors.
Feature | Specification |
---|---|
Concentration | 1 mCi/ml |
Label Position | Specifically Labeled |
Molecular Weight | 279.8 |
Receptor | Adrenoceptors |
(-)-CGP-12177 radioligand tritiated at the 5,7 position. CGP-12177 acts as an antagonist at the β1- and β2-adrenoceptors and a partial agonist at β3-adrenoceptors.
(-)-CGP-12177 is a high affinity antagonist of both β1- and β2-adrenoceptors, and functions as a partial agonist at β3-adrenoceptors. These receptors are part of a group of beta adrenergic G-protein coupled receptors (GPCRs) found in adipose tissue, heart tissue, and vascular smooth muscle tissue that play a role in cardiac output, hormone release, smooth muscle relaxation, and lipolysis. Beta adrenergic receptors have been identified as potential drug targets for congestive heart failure, hypertension, asthma, COPD, and neoplasia.
We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (Bmax), dissociation constants (Kd), association and dissociation rates (kon and koff), and inhibitor constants (Ki) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.
Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.
References for NET1061:
Concentration |
1 mCi/ml
|
---|---|
Molecular Weight |
279.8
|
Application |
Drug Discovery & Development
|
---|---|
Brand |
NEN Radiochemicals
|
Buffer/Solvent |
Ethanol
|
Detection Modality |
Radiometric
|
Label Position |
Specifically Labeled
|
Packaging |
NENSure vial
|
Radioisotope |
3H
|
Receptor |
Adrenoceptors
|
Shipping Conditions |
Shipped in Dry Ice
|
Special Ordering Information |
This is a radioactive product - shipping address must have a license to receive radioactive materials.
|
Storage Conditions |
-20°C
|
Therapeutic Area |
CNS & Neurologic
|
Unit Size |
250 µCi
|
Are you looking for resources, click on the resource type to explore further.
We are here to answer your questions.